Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2022 Earnings Conference Call August 9, 2022 11:30 AM ET

Company Participants

Brett Monia - Chief Executive Officer

Beth Hougen - Chief Financial Officer

Richard Geary - Executive Vice President of Development

Eric Swayze - Executive Vice President of Research

Eugene Schneider - Chief Clinical Development Officer

Onaiza Cadoret - Chief Global Product Strategy & Operations Officer

Conference Call Participants

Yanan Zhu - Wells Fargo

Jessica Fye - JPMorgan

Do Kim - Piper Sandler

Gena Wang - Barclays

I-Eh Jen - Laidlaw & Co.

Luca Issi - RBC

Myles Minter - William Blair

Yaron Werber - Cowen

Joseph Stringer - Needham & Co.

Gary Nachman - BMO Capital Markets

Operator

Good morning, and welcome to the Ionis Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Julie Tepper [ph], Investor Relations, to lead off the call. Please begin.

Unidentified Company Representative

Thank you, Betsy. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today's call.

With me this morning are Brett Monia, Chief Executive Officer; Doug Hougen, Chief Financial Officer; and Richard Geary, Executive Vice President of Development. And joining us for the Q&A portion of the call are Eric Swayze, Executive Vice President of Research; Eugene Schneider, Chief Clinical Development Officer; and Onaiza Cadoret, Chief Global Product Strategy and Operations Officer.

I would like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I'll turn the call over to Brett.

Brett Monia

Thanks, Julie. Good morning, everyone, and thanks for joining us today. In the first half of this year, we moved significantly closer to delivering an abundance of transformational medicines to the market. The first half was highlighted by the positive results from the Phase III NEURO-TTRansform study of eplontersen in patients with TTR polyneuropathy.